Amphastar Pharmaceuticals (AMPH) Q1 2026 earnings summary

Executive summary

• Net revenues for Q1 2026 were $171.2 million, nearly flat year-over-year, as new product launches and stable base business offset pricing and product mix pressures.

• Net income fell sharply to $6.4 million ($0.14/share), with adjusted non-GAAP net income at $19.5 million ($0.42/share), due to margin compression and higher operating expenses.

• Commercial execution remained strong for branded and differentiated products, with BAQSIMI and Primatene MIST showing solid demand despite pricing pressures.

• Strategic focus remains on business resilience, portfolio expansion, and advancing a pipeline of complex and proprietary products, supported by significant R&D investment.

• Commercial foundation strengthened by the approval and launch of Ipratropium Bromide HFA and exclusive licensing for a synthetic corticotropin compound.

Financial highlights

• Q1 2026 revenues were $171.2 million, up $0.6 million year-over-year, with gross profit declining to $70.3 million and gross margin dropping to 41.1% from 50.0% due to lower average selling prices and higher manufacturing costs.

• Operating income fell to $13.6 million from $37.3 million year-over-year; diluted EPS was $0.14, down from $0.51.

• Operating cash flow was $47.8 million in Q1.

• General and administrative expenses increased 13% to $18.0 million, and R&D expenses grew 33% to $26.7 million, including a $2.0 million upfront licensing payment.

• Share repurchases totaled $29.5 million, representing about 3% of share count.

Outlook and guidance

• BAQSIMI revenue growth expected to be flat to low single-digit percent for 2026 due to pricing pressures; peak annual sales projected at $250M–$275M.

• Overall corporate sales guidance maintained at mid- to high-single digit unit growth, supported by new product launches.

• Primatene MIST forecasted for high single-digit growth in 2026.

• Insulin aspart biosimilar and GLP-1 ANDA launches remain on track for 2027.

• Management expects continued R&D investment and rising expenses as clinical trials and product development accelerate.